Log In
BCIQ
Print this Print this
 

OXS-2175

  Manage Alerts
Collapse Summary General Information
Company Oxis International Inc.
DescriptionSmall molecule against undisclosed target
Molecular Target Undisclosed
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard IndicationBreast cancer
Indication DetailsTreat triple-negative breast cancer (TNBC)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$14.4M

$0.5M

$12.8M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

03/23/2015

$14.4M

$0.5M

$12.8M

Get a free BioCentury trial today